RESUMO
ABSTRACT: The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading throughout the world. The study describes 12 patients with SARS-CoV-2 pneumonia, who developed an acute erythematous rash with nonfollicular pinhead-sized pustules, without mucosal involvement. The clinical differential diagnosis was viral rash, acute generalized exanthematous pustulosis (AGEP), or multiform erythema. computed tomography with a diagnosis of interstitial pneumonia and a respiratory tract sample positive for SARS-CoV-2 in a reverse transcriptase polymerase chain reaction assay. Patients had signs of respiratory distress and were treated with hydroxychloroquine, darunavir, ritonavir, heparin, ceftriaxone, and azithromycin. Punch biopsies showed subcorneal pustules typical of AGEP. Dermal microvascular injury and thrombosis as described in skin damage by SARS-CoV-2 infection was not observed. The direct immunofluorescence for IgG, IgA, IgM, and C3 was negative in 8 patients investigated. A polymerase chain reaction for RNA SARS-CoV-2 performed on frozen skin was negative in 5 of 6 patients. Most of our patients were treated with systemic corticosteroids. After some days (4-10), the diffuse erythema and pustules had improved. AGEP is classified as a severe cutaneous adverse reaction, provoked by drugs and acute infections. Characteristically, removal of the offending agent leads to spontaneous resolution typically in less than 15 days. The recognition of AGEP is important, in order to avoid confusion with a systemic infection and consequently to avoid incorrect treatment. Cutaneous adverse reactions to drugs are common and are major health problems worldwide causing considerable costs for health care systems. We suggest that in the patients with AGEP during SARS-CoV-2 pneumonia, viral infection is a risk factor for developing drug reaction.
Assuntos
Pustulose Exantematosa Aguda Generalizada/etiologia , Antivirais/efeitos adversos , Tratamento Farmacológico da COVID-19 , Pele/efeitos dos fármacos , Pustulose Exantematosa Aguda Generalizada/tratamento farmacológico , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/virologia , Corticosteroides/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Biópsia , COVID-19/diagnóstico , COVID-19/imunologia , COVID-19/virologia , Teste de Ácido Nucleico para COVID-19 , Diagnóstico Diferencial , Feminino , Interações Hospedeiro-Patógeno , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Fatores de Risco , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/imunologia , Pele/imunologia , Pele/patologia , Pele/virologia , Resultado do TratamentoRESUMO
BACKGROUND: Distinguishing acute generalized exanthematous pustulosis (AGEP) and pustular psoriasis (PS) can be challenging. Staining for plasmacytoid dendritic cells, or PDCs (producer of IFN-α/ß), and MxA (an IFN-α/ß inducible protein) may help discriminate these entities. METHODS: Forty-three cases of AGEP and PS were compiled from two academic institutions. All cases were examined for CD123+ PDCs, eosinophils, acanthosis, papillomatosis, suprapapillary plate thinning, tortuous dilated capillaries, single necrotic keratinocytes, papillary dermal edema, vasculitis, eosinophil exocytosis, intraepidermal pustules, and subcorneal pustules. A subset of cases (n = 26) was stained for MxA. RESULTS: Perivascular and intraepidermal PDCs, dilated tortuous vessels, and MxA expression in the dermal inflammatory infiltrate were significantly (P < 0.05) in favor of a diagnosis of PS. The absence of PDCs and presence of eosinophils favored a diagnosis of AGEP (P < 0.05). CONCLUSIONS: We found compelling evidence for the use of CD123 to highlight PDCs in these cases. The presence of PDCs and expression of MxA in dermal inflammatory infiltrate, as well as absence of eosinophils and presence of tortuous dilated capillaries favored a diagnosis of PS. Expression of MxA in the dermal infiltrate corresponds with a Th1 pathway in PS and may indicate a Th1 component in the early initial phase of AGEP.
Assuntos
Pustulose Exantematosa Aguda Generalizada , Células Dendríticas , Proteínas de Resistência a Myxovirus/imunologia , Psoríase , Dermatopatias Vesiculobolhosas , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/patologia , Células Dendríticas/imunologia , Células Dendríticas/patologia , Feminino , Humanos , Masculino , Psoríase/diagnóstico , Psoríase/imunologia , Psoríase/patologia , Dermatopatias Vesiculobolhosas/diagnóstico , Dermatopatias Vesiculobolhosas/imunologia , Dermatopatias Vesiculobolhosas/patologia , Células Th1/imunologia , Células Th1/patologiaRESUMO
BACKGROUND: Acute Generalized Exanthematous Pustulosis (AGEP) is a rare dermatologic reaction characterized by an erythematous rash with pustular erosions, fever and leukocytosis. Although most often secondary to antibiotic use, AGEP has also been associated with many drugs. A thorough literature search showed only four previously documented cases of ibuprofen-associated AGEP, and one case of dog bite-associated AGEP. CASE REPORT: We present the case of a 46â¯year old Caucasian female who developed AGEP after self-treating with ibuprofen for a dog bite. CONCLUSION: In the clinical setting this rash is often dramatic and illuminating the causative agent can be a diagnostic challenge. Our case represents a rare cause of AGEP and an important finding for current practitioners.
Assuntos
Pustulose Exantematosa Aguda Generalizada/patologia , Analgésicos não Narcóticos/efeitos adversos , Analgésicos não Narcóticos/uso terapêutico , Mordeduras e Picadas/patologia , Ibuprofeno/efeitos adversos , Dor/tratamento farmacológico , Pustulose Exantematosa Aguda Generalizada/etiologia , Pustulose Exantematosa Aguda Generalizada/imunologia , Analgésicos não Narcóticos/administração & dosagem , Animais , Antibacterianos , Mordeduras e Picadas/tratamento farmacológico , Mordeduras e Picadas/imunologia , Cães , Feminino , Febre , Humanos , Ibuprofeno/administração & dosagem , Pessoa de Meia-Idade , Resultado do TratamentoAssuntos
Pustulose Exantematosa Aguda Generalizada/imunologia , Citocinas/imunologia , Imunidade Inata , Síndrome de Stevens-Johnson/imunologia , Pustulose Exantematosa Aguda Generalizada/patologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Síndrome de Stevens-Johnson/patologiaAssuntos
Pustulose Exantematosa Aguda Generalizada/genética , Anticonvulsivantes/efeitos adversos , Epilepsia/tratamento farmacológico , Antígenos HLA-B/sangue , Pustulose Exantematosa Aguda Generalizada/sangue , Pustulose Exantematosa Aguda Generalizada/etiologia , Pustulose Exantematosa Aguda Generalizada/imunologia , Alelos , Carbamazepina/efeitos adversos , Epilepsia/diagnóstico , Predisposição Genética para Doença , Antígenos HLA-B/imunologia , Humanos , Índia , Masculino , Pessoa de Meia-Idade , Fenitoína/efeitos adversosRESUMO
A 21-year-old man presented with multiple erythematous nonfollicular papules partially confluent to plaques on his breast and lower abdomen that had been present for 1 month. Grouped pustules were present under the right breast. The patient had been taking finasteride over the past 3 months for androgenetic alopecia. His medical history was negative for psoriasis. Our initial differential diagnosis included dyskeratosis follicularis Darier, allergic contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, and IgA pemphigus. The white blood cell count and differential were within the normal limits. Results of viral cultures and PCR, as well as bacterial and fungal cultures of skin lesions proved negative. A lesional biopsy specimen showed a slight psoriasiform acanthosis in association with spongiosis and infiltration of both the epidermis and dermis by neutrophils and eosinophils, resulting in formation of subcorneal, intraepidermal, and subepidermal pustules. The results of direct immunofluorescence were negative, excluding an IgA pemphigus. The result of a lymphocyte transformation test was positive for finasteride. On the basis of the time relationship between the administration of finasteride and the development of the skin disease in combination with symptoms resolution on cessation of the drug, the histologic findings, and the positive lymphocyte transformation test result, we consider this to be an unusual type of acute generalized exanthematous pustulosis defined as acute localized exanthematous pustulosis caused by finasteride. Within 4 weeks after withdrawal of finasteride, the rash resolved without any specific therapy. Transient discrete residual hyperpigmentation and scaling were present. The patient refused an oral provocation challenge.
Assuntos
Inibidores de 5-alfa Redutase/efeitos adversos , Pustulose Exantematosa Aguda Generalizada/induzido quimicamente , Finasterida/efeitos adversos , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/patologia , Adulto , Alopecia/tratamento farmacológico , Humanos , Ativação Linfocitária , Masculino , Linfócitos T/imunologia , Adulto JovemAssuntos
Pustulose Exantematosa Aguda Generalizada/etiologia , Antibacterianos/efeitos adversos , Toxidermias/etiologia , Interleucina-23/imunologia , Pele/efeitos dos fármacos , beta-Lactamas/efeitos adversos , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/tratamento farmacológico , Pustulose Exantematosa Aguda Generalizada/imunologia , Idoso , Biópsia , Toxidermias/diagnóstico , Toxidermias/tratamento farmacológico , Toxidermias/imunologia , Feminino , Humanos , Pele/imunologia , Pele/patologia , Esteroides/uso terapêutico , Resultado do TratamentoRESUMO
INTRODUCTION: Amicrobial pustulosis of the skin folds represents a new entity within the spectrum of neutrophilic dermatoses. This disease is characterized by acute onset of pustular lesions in the skin folds, association with an autoimmune disorder, and improvement under systemic corticosteroids. OBSERVATION: A 24-year-old woman had been presenting pustular dermatosis for several months involving the inguinal folds and the scalp. The pustules coalesced to form oozing and crusting plaques. Eczematous lesions were located on the trunk. She also presented macrocytic anemia related to autoimmune erythroblastopenia. Bacteriological culture was negative. Antinuclear antibodies were found with anti-SSA specificity. Histopathological examination of a skin biopsy specimen showed pustules in the epidermis together with an inflammatory dermal infiltrate. Cutaneous direct immunofluorescence testing was negative. The patient responded to systemic corticosteroids. DISCUSSION: Thirty-six cases of amicrobial pustulosis of the skin folds have been reported in the literature. All but two previously reported patients were females with an autoimmune disorder (chiefly systemic lupus erythematosus). The clinical picture is characterized by aseptic pustular lesions of the major and minor skin folds of the scalp and the anogenital area associated with eczematous lesions. Diagnostic criteria have recently been proposed. This disease responds to systemic corticosteroids. We report a new case of amicrobial pustulosis of the skin folds associated with autoimmune erythroblastopenia, which to the best of our knowledge has been described only once in the literature.
Assuntos
Pustulose Exantematosa Aguda Generalizada/diagnóstico , Anemia Hemolítica Autoimune/diagnóstico , Anticorpos Antinucleares/sangue , Pustulose Exantematosa Aguda Generalizada/tratamento farmacológico , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/patologia , Anemia Hemolítica Autoimune/tratamento farmacológico , Anemia Hemolítica Autoimune/imunologia , Anti-Inflamatórios/uso terapêutico , Autoantígenos/imunologia , Biópsia , Derme/patologia , Eczema/etiologia , Epiderme/patologia , Feminino , Humanos , Imunossupressores/uso terapêutico , Prednisona/uso terapêutico , Ribonucleoproteínas/imunologia , Senegal/etnologia , Adulto JovemRESUMO
Acute generalized exanthematous pustulosis (AGEP) is a significant adverse cutaneous reaction, most often provoked by drugs and acute infections. The recognition of AGEP is important, in order to avoid confusion with a systemic infection and consequently to avoid incorrect treatment. The clinical hallmark is the presence of multiple disseminated sterile pustules on an erythematous background, associated with fever and a massive neutrophilia and sometimes eosinophilia. The disease is characterised by an acute onset and a spontaneous resolution within 2 weeks. The involvement of drug-specific T cells in the pathomechanism can be confirmed by positive skin patch tests and lymphocyte transformation tests. In this review, we highlight the main clinical, pathophysiological and diagnostic aspects of this peculiar form of drug allergy.
Assuntos
Pustulose Exantematosa Aguda Generalizada , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/etiologia , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/fisiopatologia , Diagnóstico Diferencial , Toxidermias/diagnóstico , Toxidermias/imunologia , Toxidermias/fisiopatologia , Humanos , Testes do Emplastro , Fatores de RiscoAssuntos
Pustulose Exantematosa Aguda Generalizada/etiologia , Antagonistas Adrenérgicos/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Hipertensão Induzida pela Gravidez/tratamento farmacológico , Labetalol/efeitos adversos , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/imunologia , Antagonistas Adrenérgicos/imunologia , Adulto , Anti-Hipertensivos/imunologia , Atenolol/efeitos adversos , Atenolol/imunologia , Reações Cruzadas , Substituição de Medicamentos , Feminino , Humanos , Hipertensão Induzida pela Gravidez/diagnóstico , Labetalol/imunologia , Testes do Emplastro , Valor Preditivo dos Testes , Gravidez , Terceiro Trimestre da GravidezAssuntos
Pustulose Exantematosa Aguda Generalizada/etiologia , Hipersensibilidade a Drogas/etiologia , Iohexol/análogos & derivados , Pustulose Exantematosa Aguda Generalizada/imunologia , Administração Intravenosa , Adulto , Hipersensibilidade a Drogas/imunologia , Feminino , Humanos , Iohexol/efeitos adversosRESUMO
Acute generalized exanthematous pustulosis (AGEP) is an uncommon disease, which presents as a nonfollicular erythematous sterile pustular eruption. More than 90% of the cases are induced by adverse drug reactions, often triggered by anti-infectious systemic drugs. We report a case of itraconazole-induced AGEP in a 22-year-old man, with an assessment of his cytokine/chemokine production and drug-specific cell reactivity. We found that AGEP, like other T cell-mediated drug eruptions, alters the immunological status of the patient, probably favouring T-cell activation, recruitment and regulation. Few cases of itraconazole-induced AGEP have been described in the literature, and to our knowledge, this is the first report in which the cellular immunological features are assessed.
Assuntos
Pustulose Exantematosa Aguda Generalizada/imunologia , Antifúngicos/efeitos adversos , Toxidermias/imunologia , Itraconazol/efeitos adversos , Ativação Linfocitária/imunologia , Pustulose Exantematosa Aguda Generalizada/induzido quimicamente , Humanos , Masculino , Linfócitos T/fisiologia , Adulto JovemAssuntos
Pustulose Exantematosa Aguda Generalizada/imunologia , Haptenos/imunologia , Células Th17/imunologia , beta-Lactamas/imunologia , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/metabolismo , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Células Th17/metabolismoRESUMO
Among diagnostic progress over the last three years in internal medicine, Antisynthetase Syndrome is now more easily recognised with the diffusion of laboratory tests for research of antibodies against tRNA synthetases (Anti JO1, anti PL7, Anti PL12). In two third of cases, these antibodies are found despite absence of antinuclear antibodies. Hence, we have to search them specifically in patients with polyarthritis associated with myositis, cutaneous manifestations (Raynaud phenomenom and "mechanic'hands") and interstitial lung disease. Discovery of asymptomatic mutation in the L ferritin coding sequence help us to better understand the "unexplained" hyperferritinemia. Initially described by japonese gastroenterologists, auto immune pancreatitis in fact a part of a systemic sclerosing disease with a biochemical hallmark: in crease of a subclass of immunoglobulins G (IgG4). A new pediatric disease due to a deficiency of the interleukin1 receptor antagonist (multifocal aseptic osteitis, periostitis, stomatitis, disseminated pustulosis) help us to better understand unexplained auto inflammatory diseases. The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.
Assuntos
Doenças Autoimunes/diagnóstico , Doenças Autoimunes/imunologia , Medicina Interna/tendências , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/imunologia , Aminoacil-tRNA Sintetases/imunologia , Anticorpos Monoclonais/uso terapêutico , Artrite/diagnóstico , Artrite/imunologia , Autoanticorpos/imunologia , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/genética , Biomarcadores/metabolismo , Quimioterapia Combinada , Ferritinas/genética , Humanos , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Interleucina-6/antagonistas & inibidores , Sobrecarga de Ferro/diagnóstico , Sobrecarga de Ferro/genética , Doenças Pulmonares Intersticiais/diagnóstico , Doenças Pulmonares Intersticiais/imunologia , Mutação , Miosite/diagnóstico , Miosite/imunologia , Osteíte/diagnóstico , Osteíte/imunologia , Pancreatite/diagnóstico , Pancreatite/imunologia , Periostite/diagnóstico , Periostite/imunologia , Doença de Raynaud/diagnóstico , Doença de Raynaud/imunologia , Estomatite/diagnóstico , Estomatite/imunologia , Síndrome , Resultado do TratamentoRESUMO
Cutaneous adverse drug reactions are unpredictable and include various different skin conditions of varying degrees of severity. The most concerning are usually referred to as severe cutaneous adverse reactions (SCARs) and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS) or hypersensitivity syndrome (HSS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). All are delayed type IV hypersensitivity reactions in which a T-cell-mediated drug-specific immune response is responsible for causing the disease. Nonetheless, specific T-cell subpopulations develop in response to certain environmental conditions and produce cytokines that orchestrate the various phenotypes. Cytotoxic T lymphocytes (CTLs), T-helper type 1 (Th1), Th2, Th17, and regulatory T cells (Treg), among other T-cell subpopulations, participate in the development of SCAR phenotypes. Cell subpopulations belonging to the innate immune system, comprising natural killer cells, innate lymphoid cells, monocytes, macrophages and dendritic cells, can also participate in shaping specific immune responses in various clinical conditions. Additionally, tissue-resident cells, including keratinocytes, can contribute to epidermal damage by secreting chemokines that attract pro-inflammatory immunocytes. The final phenotypes in each clinical entity result from the complex interactions between a variety of cell lineages, their products, soluble mediators and genetic and environmental factors. Although the pathophysiology of these reactions is not fully understood, intensive research in recent years has led to major progress in our understanding of the contribution of certain cell types and soluble mediators to the variability of SCAR phenotypes.
Assuntos
Toxidermias/imunologia , Síndrome de Hipersensibilidade a Medicamentos/imunologia , Pustulose Exantematosa Aguda Generalizada/imunologia , Pustulose Exantematosa Aguda Generalizada/patologia , Animais , Toxidermias/patologia , Síndrome de Hipersensibilidade a Medicamentos/patologia , Humanos , Imunidade InataRESUMO
IL-17E (IL-25) is a member of the IL-17 cytokine family involved in the promotion of type 2 immune responses. Recently, IL-17E has been reported to be up-regulated in distinct skin inflammatory diseases such as psoriasis and atopic and contact dermatitis. We assessed the role played by IL-17E in skin inflammation. Here, we show that IL-17E induces skin inflammation in vivo, characterized by the expression of innate immune response genes and the recruitment of innate immune cells, particularly neutrophils. Genetic deletion or IL-17E neutralization ameliorated skin inflammation induced by imiquimod application or tape stripping, with reductions in neutrophil and macrophage infiltration as assessed by t-distributed stochastic neighbor embedding-guided multiparameter flow cytometry analysis, in mice. In humans, IL-17E promotes the recruitment of neutrophils via activation of macrophages in a p38-dependent mechanism. In addition, IL-17E is up-regulated in neutrophil-rich inflammatory skin diseases, such as pyoderma gangrenosum and acute generalized exanthematous pustulosis. Our data show a role for IL-17E in skin inflammation that is unrelated to the development of type 2 immune reactions. We propose that IL-17E is an important common denominator of chronic skin inflammation, promoting innate immune cell recruitment and activation.